Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -56.74% | -123.29% | -153.09% | ||
| Total Depreciation and Amortization | 334.18% | 184.91% | 110.34% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -21.47% | 931.12% | -37.66% | ||
| Change in Net Operating Assets | 1,738.83% | -457.31% | 278.38% | ||
| Cash from Operations | 67.03% | -180.49% | -132.99% | ||
| Capital Expenditure | 86.47% | -- | -303.21% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -71,925.19% | -- | -303.21% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -100.00% | 2,615.53% | 137.37% | ||
| Cash from Financing | -100.00% | 2,615.53% | 137.37% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -- | -- | ||